The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
Open accessAbstract
BACKGROUND: Invasive fungal diseases are important causes of morbidity and mortality. Clarity and uniformity in defining these infections are important factors in improving the quality of clinical studies. A standard set of definitions strengthens the consistency and reproducibility of such studies. METHODS: After the introduction of the original European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group definitions, advances in diagnostic technology and the recognition of areas in need of improvement led to a revision of this document. The revision process started with a meeting of participants in 2003, to decide on the process and to draft the proposal. This was followed by several rounds of consultation until a final draft was approved in 2005. This was made available for 6 months to allow public comment, and then the manuscript was prepared and approved. RESULTS: The revised definitions retain the original classifications of "proven," "probable," and "possible" invasive fungal disease, but the definition of "probable" has been expanded, whereas the scope of the category "possible" has been diminished. The category of proven invasive fungal disease can apply to any patient, regardless of whether the patient is immunocompromised, whereas the probable and possible categories are proposed for immunocompromised patients only. CONCLUSIONS: These revised definitions of invasive fungal disease are intended to advance clinical and epidemiological research and may serve as a useful model for defining other infections in high-risk patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The development of standardized diagnostic criteria for invasive aspergillosis has been a major improvement for IPA (94).”
From Aspergillus fumigatus and Aspergillosis in 2019 (2019) · cites this paper as [94]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Self-citationWalsh, T. J., Anaissie, E. J., Denning, D. W., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Segal, B. H., Steinbach, W. J., Stevens, D. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/525258 · Cited by 2,705
Self-citationAşçıoğlu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Billé, J., Crokaert, F., Denning, D. W., Donnelly, J. P., Edwards, J. E., Erjavec, Z., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/323335 · Cited by 2,315
Self-citationPosaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia
Cornely, O. A., Maertens, J. A., Winston, D. J., Perfect, J. R., Ullmann, A. J., Walsh, T. J., HELFGOTT, D. C., Hołowiecki, J., Stockelberg, D., Goh, Y. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061094 · Cited by 1,802
Self-citationPosaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease
Ullmann, A. J., Lipton, J. H., Vesole, D. H., Chandrasekar, P. H., Langston, A. A., Tarantolo, S., Greinix, H., de Azevedo, W. M., Reddy, V. S., Boparai, N., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061098 · Cited by 1,339
Walsh, T. J., Pappas, P., Winston, D. J., Lazarus, H. M., Petersen, F., Raffalli, J., Yanovich, S., Stiff, P., Greenberg, R., Donowitz, G., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejm200201243460403 · Cited by 979
Self-citationWalsh, T. J., Teppler, H., Donowitz, G. R., Maertens, J. A., Baden, L. R., Dmoszyńska, A., Cornely, O. A., Bourque, M. R., Lupinacci, R. J., Sable, C. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040446 · Cited by 907
Self-citationAustin, J. H. M., Müller, N. L., Friedman, P. J., Hansell, D. M., Naidich, D. P., Rémy-Jardin, M., Webb, W. R., & Zerhouni, E. A. (1996) · Radiology · doi:10.1148/radiology.200.2.8685321 · Cited by 836
Invasive Aspergillosis Disease Spectrum, Treatment Practices, and Outcomes
Patterson, T. F., Kirkpatrick, W. R., White, M., Hiemenz, J. W., WINGARD, J. R., DUPONT, B., RINALDI, M. G., STEVENS, D. A., & Graybill, J. R. (2000) · Medicine · doi:10.1097/00005792-200007000-00006 · Cited by 791
Self-citationCornely, O. A., Maertens, J. A., Bresnik, M., Ebrahimi, R., Ullmann, A. J., Bouza, E., Heußel, C. P., Lortholary, O., Rieger, C. T., Boehme, A., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/514341 · Cited by 744
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 1,001–1,024 of 1,024
Molecular Imaging of Invasive Pulmonary Aspergillosis Using ImmunoPET/MRI: The Future Looks Bright
Thornton, C. R. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00691 · Cited by 47
Kuster, S., Stampf, S., Gerber, B., Baettig, V., Weisser, M., Gerull, S., Medinger, M., Passweg, J., Schanz, U., Garzoni, C., et al. (2018) · Transplant Infectious Disease · doi:10.1111/tid.12981 · Cited by 48
Lupiañez, C. B., Canet, L. M., Carvalho, A., Alcazar-Fuoli, L., Springer, J., Lackner, M., Segura-Catena, J., Comino, A., Olmedo, C., Ríos, R., et al. (2016) · Infection and Immunity · doi:10.1128/iai.01359-15 · Cited by 42
Dobias, R., Jaworska, P., Tomaskova, H., Kanova, M., Lyskova, P., Vrba, Z., Holub, C., Svobodová, L., Hamal, P., & Raska, M. (2018) · Mycoses · doi:10.1111/myc.12765 · Cited by 42
Robin, C., Cordonnier, C., Sitbon, K., Raus, N., Lortholary, O., Maury, S., Peffault de la Tour, R., Bretagne, S., & Bastuji-Garin, S. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.09.028 · Cited by 38
Self-citationZhang, L., Guo, Z., Xie, S., Zhou, J., Chen, G., Feng, J., & Huang, Y. (2019) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2018.08.005 · Cited by 36
Denis, B., Guiguet, M., de Castro, N., Mechaï, F., Revest, M., Melica, G., Costagliola, D., & Lortholary, O. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ492 · Cited by 33
Self-citationChumpitazi, B. F. F., Lebeau, B., Faure-Cognet, O., Hamidfar-Roy, R., Timsit, J.-F., Pavese, P., Thiebaut-Bertrand, A., Quesada, J.-L., Pelloux, H., & Pinel, C. (2014) · Medical Mycology · doi:10.1093/mmy/myu018 · Cited by 31
Miceli, M. H., Goggins, M. I., Chander, P., Sekaran, A. K., Kizy, A. E., Samuel, L., Jiang, H., Thornton, C. R., Ramesh, M., & Alangaden, G. (2015) · Mycoses · doi:10.1111/myc.12327 · Cited by 30
The current management landscape: aspergillosis: Table 1.
Maertens, J. A., Blennow, O., Duarte, R. F., & Muñoz, P. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw393 · Cited by 29
Self-citationDiagnostic Approaches for Invasive Aspergillosis—Specific Considerations in the Pediatric Population
Lehrnbecher, T., Hassler, A., Groll, A. H., & Bochennek, K. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00518 · Cited by 29
“Similar to GM, the EORTC/MSG consensus group included BG as mycological criterion in the revised definitions of IFD (De Pauw et al., 2008).”
BackgroundMethodResultInfluentialUse of 1,3-β-D-glucan in invasive fungal diseases in hematology patients
Giacobbe, D. R., Del Bono, V., Viscoli, C., & Mikulska, M. (2017) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2017.1401467 · Cited by 27
Self-citationDiagnostics and Susceptibility Testing in Aspergillus
Bernal-Martínez, L., Alastruey-Izquierdo, A., & Cuenca-Estrella, M. (2016) · Future Microbiology · doi:10.2217/fmb.15.140 · Cited by 25
Huang, L., He, H., Jin, J., & Zhan, Q. (2017) · BMC Infectious Diseases · doi:10.1186/s12879-017-2307-y · Cited by 25
Darouiche, R. O. (2009) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2009.02.013 · Cited by 23
Çakır, N., & Koc, A. N. (2021) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.20210475 · Cited by 21
Sugui, J. A., Rose, S. R., Nardone, G., Swamydas, M., Lee, C.-C. R., Kwon-Chung, K. J., & Lionakis, M. S. (2017) · Scientific Reports · doi:10.1038/s41598-017-10888-9 · Cited by 21
Lum, L., Lee, A., Vu, M., Strasser, S., & Davis, R. (2020) · Transplant Infectious Disease · doi:10.1111/tid.13361 · Cited by 22
Yeoh, S. F., Lee, T. J., Chew, K. L., Lin, S., Yeo, D., & Setia, S. (2018) · Infection and Drug Resistance · doi:10.2147/idr.s165676 · Cited by 20
Wang, Y., Yang, M., Xia, Y., Yan, J., Zou, J., & Zhang, D. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06678-4 · Cited by 16
Invasive Aspergillosis in Hematological Patients
Kimura, S.-I. (2016) · Medical Mycology Journal · doi:10.3314/mmj.57.j77 · Cited by 14
Hammarström, H., Stjärne Aspelund, A., Christensson, B., Heußel, C. P., Isaksson, J., Kondori, N., Larsson, L., Markowicz, P., Richter, J., Wennerås, C., et al. (2018) · Mycoses · doi:10.1111/myc.12773 · Cited by 15
How do I manage refractory invasive pulmonary aspergillosis
Vergidis, P., Sendi, P., Alkhateeb, H. B., & Nguyen, M. H. (2024) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2024.01.015 · Cited by 12
PCR Technology for Detection of Invasive Aspergillosis
Barnes, R., & White, P. (2016) · Journal of Fungi · doi:10.3390/jof2030023 · Cited by 8
“Consensus definitions of invasive mould disease have been developed by the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group [8].”
Method
Metadata
- Authors
- De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., Kauffman, C. A., Denning, D. W., Patterson, T. F., Maschmeyer, G., Bille, J., Dismukes, W. E., Herbrecht, R., Hope, W. W., Kibbler, C. C., Kullberg, B. J., Marr, K. A., Muñoz, P., Odds, F. C., Perfect, J. R., Restrepo, A., Ruhnke, M., Segal, B. H., Sobel, J. D., Sorrell, T. C., Viscoli, C., Wingard, J. R., Zaoutis, T., & Bennett, J. E.
- Affiliations
- Radboud University Medical Center (NL)
- Corresponding author
- Donnelly, J. Peter
- ORCID
- Walsh, Thomas J.
- Donnelly, J. Peter
- Stevens, David A.
- Edwards, John E.
- Calandra, Thierry
- Pappas, Peter G.
- Maertens, Johan
- Lortholary, Olivier
- Denning, David W.
- Patterson, Thomas F.
- Maschmeyer, Georg
- Herbrecht, Raoul
- Hope, William W.
- Kullberg, Bart Jan
- Marr, Kieren A.
- Perfect, John R.
- Ruhnke, Markus
- Segal, Brahm H.
- Sobel, Jack D.
- Sorrell, Tania C.
- Wingard, John R.
- Zaoutis, Theoklis
- Bennett, John E.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-06-15
- Volume
- 46
- Issue
- 12
- Pages
- 1813-1821
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC2671227
- OpenAlex
- W2166734004
- Cited by
- 4,917
- References
- 28
- Citations by year
- 2026: 85 · 2025: 146 · 2024: 169 · 2023: 172 · 2022: 203 · 2021: 280 · 2020: 362 · 2019: 424 · 2018: 383 · 2017: 354 · 2016: 345 · 2015: 376 · 2014: 363 · 2013: 299 · 2012: 279
- FWCI
- 140.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Institutional Repository University of Antioquia (University of Antioquia) (publishedVersion, cc-by-nc-nd)
- PubMed Central (acceptedVersion)
- IRIS (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Funders
- Amgen
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Children's Hospital of Philadelphia
- Wayne State University
- University of Pennsylvania
- Wellcome Trust
- Valeant Pharmaceuticals International
- European Commission
- University of Aberdeen
- European Organisation for Research and Treatment of Cancer
- Astellas Pharma
- Centre Hospitalier Universitaire Vaudois
- Basilea Pharmaceutica
- Italfarmaco
- National Institutes of Health
- University at Buffalo
- Medical School, University of Michigan
- University of Texas Health Science Center at San Antonio
- Medical Research Council
- National Health and Medical Research Council
- National Institute of Allergy and Infectious Diseases (Z01AI000654)
- Janssen Pharmaceuticals
- UCB Pharma
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Oncology › Neutropenia and Cancer Infections
- Keywords
- invasive fungal infections, diagnostic definitions, immunocompromised patients, clinical trial endpoints, fungal epidemiology
- MeSH terms
- Humans, Mycoses, Terminology as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
